©
sturti
E+
A first stem cell transplant after CAR-T-cell therapy reduces relapses
Jatros Digital
30
Min. Lesezeit
01.12.2018
Weiterempfehlen
<p class="article-intro">In a new study, patients with acute lymphocytic leukemia (ALL) who received a first stem cell transplant after CD19 CAR-T-cell therapy were less likely to experience a relapse when compared to similar patients who didn’t undergo transplantation.</p>
<hr />
<p class="article-content"><p>In this phase I/II trial 64 ALL-patients were analyzed who had received an infusion of their own T-cells that had been reprogrammed to recognize and target CD19. Patients had previously relapsed or had not responded to other treatment. Follow-up monitoring occurred for at least one year.<br /> 14 patients relapsed, died, or did not respond to the CAR-T-cell therapy. Of the 50 patients who achieved a sustained remission after CAR-T-cell therapy, 34 had a history of previous stem cell transplant.<br /> There were several cohorts observed:</p> <ul> <li>Of 24 patients who had a previous stem cell transplant but did not undergo a second one following CAR-T-cell therapy, 7 remain in remission.</li> <li>Among the 10 patients who had their second stem cell transplant following CAR-T-cell therapy, 5 remain alive and in remission after at least 24 months of follow-up.</li> <li>Among the 16 patients who had not had a previous stem cell transplant, 13 had one after receiving CAR-T-cell therapy. One of these patients relapsed following the stem cell transplant.</li> <li>Of the 3 patients who did not have a stem cell transplant after CAR-T-cell therapy, two relapsed and the third remains in remission after 28 months of follow-up.</li> </ul> <p>One of the expected effects of CAR-T-cell therapy is B-cell aplasia. Continued B-cell aplasia is regarded as an indicator that the CAR-T-cells are still actively preventing the patient’s cancer from coming back. By contrast, short B-cell aplasia indicates that the CAR-T-cells may no longer be working.<br /> In the current analysis of patients who had been followed for at least a year, those with short B-cell aplasia who had a stem cell transplant after CAR-T-cell therapy were less likely to relapse, regardless of whether the transplant was their first or their second. In this group of 8 patients, 1 died of transplant-related complications and 2 relapsed. By contrast, all 6 patients with short B-cell aplasia who did not undergo stem cell transplant after CAR-T-cell therapy relapsed.<br /> Among patients who had a stem cell transplant after CAR-T-cell therapy, all relapses thus far have occurred within two years, said Dr. Summers. However, among patients who did not have a stem cell transplant following CAR-T-cell therapy, relapses continue to occur two or more years after treatment.<br /> „For pediatric patients who achieve remission after CAR-T-cell therapy, undergoing a first stem cell transplant following CD19 CAR-T-cell therapy appears to be beneficial,‟ said Dr. Summers. „For patients who achieve remission, but have a higher risk of relapse because of short B-cell aplasia, a stem cell transplant after CAR-T-cell therapy appears to be beneficial whether or not they have had one previously.‟<br /> For patients with a previous stem cell transplant, the benefit of a second one after CAR-T-cell therapy is unclear; it may be that among this group of patients, only those with short B-cell aplasia benefit from a second transplant, according to the authors.<br /> Longer follow-up is needed to understand the reasons for long-term relapse after CD19 CAR-T-cell therapy and whether patients with a prior stem cell transplant can benefit from receiving a second one following CAR-T-cell therapy. Phase II of the trial, now underway, is testing the anti-CD19 CAR-T-cell therapy in a larger group of patients with acute leukemia or lymphoma that has relapsed or been unresponsive to other therapy.</p> <p><br /><strong>Reference:</strong><br />Summers C et al.: long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR-T cell induced remission. ASH Annual Meeting 2018, abstract #967</p></p>
Das könnte Sie auch interessieren:
Hinweise auf schlechteren Verlauf bei Männern bestätigt
Obwohl Frauen häufiger an einer Lupusnephritis erkranken, scheint diese bei Männern schwerer zu verlaufen. Diese Hypothese wird von einer Metaanalyse der Universität Minnesota unterstützt.1 Männer bekamen häufiger eine Nephritis vom Grad IV ± V, hatten schlechtere Nierenparameter und eine geringere Wahrscheinlichkeit für eine komplette Remission.
Le rôle de l’imagerie dans la sarcoïdose cardiaque
La sarcoïdose cardiaque est une maladie cardiaque inflammatoire rare, mais importante. Le tableau clinique peut être très variable, allant de manifestations subcliniques à une gêne ...
Frühe, aggressive Therapie ist entscheidend
Frauen erkranken zwar häufiger an einer Lupusnephritis, aber Studien weisen darauf hin, dass die Krankheit bei Männern schwerer verläuft. Diese Hypothese wird durch eine neue Metaanalyse ...